AnorMED Reports Progress on Mozobil Study
AnorMED has reported that additional clinical trial sites have been added to the company’s Mozobil Phase III clinical trials. AnorMED is also recruiting patients into five Phase II trials for Mozobil, including trials in Germany and Canada, and plans to initiate one new Phase II trial by the end of 2005.
Article
Stem Cell Therapeutics and Medicon Get Approval to Begin Stroke Drug Study
Stem Cell Therapeutics (SCT) and Medicon have received approval to begin the Phase I clinical study in SCT’s NTx-265 program for the treatment of stroke. The Danish Medicines Agency (DMA) and the Institutional Review Board (IRB) have both responded to the study protocol submission with written consent.
Article
ProtoKinetix AAGP(TM) Cosmetic Applications Enhanced by Preservation of Adult Skin Cells
ProtoKinetix, Inc. (OTCBB:PKTX) announces today that further tests of the effect of AAGP(TM) on skin cells demonstrate an ability to maintain and preserve the viability of adult skin cells.
Article
RenaMed Biologics Reports Positive Phase II Data With Renal Bio-Replacement Therapy; Phase II study results show improved survival rates in patients with Acute Renal Failure
RenaMed Biologics, Inc. (RenaMed(TM)) reported today at the American Society of Nephrology preliminary positive findings from a Phase II, controlled randomized study of its Renal Bio-Replacement Therapy to treat patients with acute renal failure (ARF or acute kidney injury).
Article
Introgen Therapeutics, Inc.’s INGN 241 Works Synergistically With Celebrex(R) To Kill Breast Cancer Cells
Introgen Therapeutics, Inc. (Nasdaq: INGN) today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex(R)) marketed by Pfizer (NYSE: PFE) to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.
Article
New Clinical Trial to Begin for Chronic Lymphocytic Leukemia Using Argos’ Personalized Dendritic Cell Vaccine
Immunotherapy pioneer Argos Therapeutics in conjunction with Toronto-based DC Bio Corp., announced that a clinical trial for chronic lymphocytic leukemia (CLL) is scheduled to begin in Q1 2006 using Argos’s proprietary RNA-loaded dendritic cell vaccine technology.
Article
Vical Incorporated Receives $1 Million Payment From Merck & Co., Inc. On Start Of Cancer DNA Vaccine Trial
Vical Incorporated announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck’s initiation of a Phase I clinical trial of a DNA cancer vaccine.
Article
ThermoGenesis And Medtronic, Inc. Sign Thrombin Processing Device(TM) (TPD(TM)) Agreement
ThermoGenesis Corp. announced today that the Company has signed a worldwide OEM Supply Agreement with Medtronic, Inc. Under the agreement, ThermoGenesis Corp. will supply its TPD to Medtronic for sale by Medtronic.
Article
Vitro Announces Advances in Its Stem Cell Technology
Vitro Diagnostics, Inc. (OTC BB: VODG), dba Vitro Biopharma, announced completion of significant milestones in the development of its stem cell technology for use in diabetes treatment.
Article
Bio-Matrix Scientific Sees Completion of New Stem Cell Cryogenic Labs in December
Bio-Matrix’ new 15,000 sq. ft. facility, located in the heart of the San Diego biotechnology corridor, is currently in the process of being upgraded in order to house the Company’s state-of-the-art secure Cryogenic Stem Cell Bank, 3 Research labs, aseptic cellular/tissue processing rooms, hematology, microbiology and flow cytometry laboratories.
Article
Sigma-Aldrich Corporation (SIAL) Names Jai Nagarkatti Chief Executive Officer Effective January 1, 2006
The Sigma-Aldrich Corporation’s Board of Directors announced today the appointment of Jai Nagarkatti, 58, (President and Chief Operating Officer) as President and Chief Executive Officer effective January 1, 2006.
Article
Transgenic Software Releases Technical White Paper for its Flagship Product Villager Transgenic Animal Management System
Villager Transgenic Animal Management Systems colony management module, integrates the best practices of transgenic science with the advanced tools of computer science to assist research companies in the discovery process.
Article